Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 10/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601268 | 0.98 | TAAR1 (0.36) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3601527 | 0.95 | TAAR1 (0.40) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2415899 | 0.88 | CYP2D6 (0.36) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2701783 | 0.83 | CYP2D6 (0.33) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4297604 | 0.81 | CYP2D6 (0.34) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2328184 | 0.81 | KCNH2 (0.31) | — | |
| SCHEMBL2325661 | 0.78 | CA1 (0.40) | — | |
| SCHEMBL4290513 | 0.77 | CYP2D6 (0.40) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6284637 | 0.76 | TAAR1 (0.43) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4933742 | 0.75 | TAAR1 (0.39) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450352-B2 | Thiazole compounds and their use for inhibiting phosphodiesterase 4, TNF-α, and IL-4 | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20100094002-A1 | Thiazole Compound and Use Thereof | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-04-15 | — | — | US | disclosed |
| US-7655680-B2 | (E)-3-[2-(3,4-diethoxyphenyl)thiazole-4-yl]-1-(2-methoxyphenyl)propenone; inhibiting the activity of phosphodiesterase 4, the production of tumor necrosis factor alpha, and the production of interleukin 4; atopic dermatitis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20080039511-A1 | Thiazole Compound and Use Thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1748044-A1 | THIAZOLE COMPOUND AND USE THEREOF | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094002-A1 | Thiazole Compound and Use Thereof | PDE3B, IL4, PDE4A | TAAR1 1152/4885CYP2D6 331/4885SLC6A2 3308/4885 |
| US-20080039511-A1 | Thiazole Compound and Use Thereof | PDE3B, PDE3A, PDE4A | TAAR1 779/4885CYP2D6 211/4885SLC6A2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.